drugset / Trial / NCT02430363
Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
Phase 1/2
Unknown
58 enrolled
Medical Research Council
Aarhus University Hospital · collabECCO - the European CanCer Organisation · collabMerck Sharp & Dohme LLC · collabNCRI Clinical Studies Groups · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
It is known that after application of MK-3475 activated PD -1 negatively regulates the activation of T cells through suppression of the path of PI3K / Akt. This study will identify the effectiveness of oral inhibitors of PI3K / Akt pathway in comparison with MK-3475 (pembrolizumab).
Timeline
- Start
- 2013-03
- Primary completion
- 2016-01
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dactolisib | Small molecule | — | Oral |
| Subject | Ipatasertib | Small molecule | — | Oral |
| Comparator | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Pictilisib | Small molecule | — | Oral |